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Lipoprotein(a) (Lp(a)) is an atherosclerosis-causing 
lipoprotein that circulates in human plasma as a com- 
plex of low density lipoprotein (LDL) and apolipopro- 
tein(a) (apo(a)). It is not known whether apo(a) at- 
taches to LDL within hepatocytes prior to secretion or 
in plasma subsequent to secretion. Here we describe 
the development of a line of mice expressing the human 
apo(a) transgene under the control of the murine trans- 
ferrin promoter. The apo(a) was secreted into the 
plasma, but circulated free of lipoproteins. When  hu- 
man (h)-LDL was injected intravenously, the circulat- 
ing apo(a) rapidly associated with the lipoproteins, as 
determined by nondenaturing gel electrophoresis. Hu- 
man HDL and  mouse  LDL  had  no such effect. When h- 
VLDL was injected, there was a delayed association of 
apo(a) with the lipoprotein fraction which suggests 
that apo(a) preferentially associated with a metabolic 
product of VLDL. The complex of apo(a) with LDL 
formed both in  vivo and in  vitro was resistant to boiling 
in the presence of detergents and denaturants, but was 
resolved upon disulfide reduction. These studies sug- 
gest that apo(a) fails  to associate with mouse lipopro- 
teins due  to structural differences  between human  and 
mouse LDL, and that Lp(a) formation can occur in 
plasma through the association of apo(a) with circulat- 
ing LDL. 
Lipoprotein(a) is a cholesterol ester-rich particle comprised 
of a low density lipoprotein (LDL)’ and a highly polymorphic 
glycoprotein called apolipoprotein(a)  (apo(a)) (1, 2). The 
apo(a) of Lp(a) is attached to apolipoprotein B-100 (apoB- 
100) by a putative disulfide linkage (3-5), although other 
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interactions may contribute to  the tight association of these 
two proteins (6, 7). The site of assembly of the  Lp(a) particle 
in  uiuo is not known. Apo(a) and apoB-100 mRNA are both 
expressed in significant quantities only in the liver (8, 9). 
Metabolic studies suggest that unlike LDL, Lp(a) is not 
initially secreted as  a triglyceride-rich lipoprotein (10). It is 
not known if apo(a) couples to apoB in the hepatocyte and is 
secreted as  a pre-formed lipoprotein, or whether apo(a) joins 
the lipoprotein particle  in the plasma. Individuals with abe- 
talipoproteinemia are unable to secrete apoB-100 and yet 
have apo(a) in their plasma which circulates free of lipopro- 
teins (11). Therefore, apo(a) can be secreted from the liver 
independently of apoB-100. 
The physiological  role of Lp(a) remains elusive. Lp(a) has 
an unusual species distribution  and is present in the plasma 
of the hedgehog (12), marmoset (13), old  world monkeys (8, 
14), great apes (14),  and humans ( l ) ,  but  not in other animals. 
To date, the only experimental animal models available to 
study the in  uiuo metabolism and pathophysiology of Lp(a) 
have been primates. In order to study the site of formation 
and metabolism of Lp(a) and its role in atherogenesis, we 
have established a transgenic mouse line expressing the hu- 
man apo(a) under the control of the mouse transferrin pro- 
moter. 
EXPERIMENTAL  PROCEDURES 
Materiak-Human  LDL  (density (d )  = 1.019-1.063 g/ml),  VLDL 
(d < 1.006 g/ml), and  HDL  (d = 1.063-1.215 g/ml) were prepared  as 
previously  described (15). IgG-lA’, an anti-human apo(a) mouse 
monoclonal antibody, was obtained from  Dr. Gerd  Utermann  (Inns- 
bruck,  Austria). A  polyclonal rabbit  anti-human  apoE  antibody was 
obtained from  Dr. Carl Weisgraber (Gladstone  Institute, University 
of San Francisco, San Francisco,  CA), and goat anti-rabbit IgG was 
obtained from  Cappell (Durham,  NC).  [a-”PIdCTP  and [-y-”PIATP 
were purchased from ICN Radiochemicals (Irvine, CA). Restriction 
enzymes and Escherichia coli DNA  polymerase I (Klenow fragment) 
were obtained  from New England Biolabs  (Beverly,  MA). The nylon 
and nitrocellulose membranes were from  Schleicher & Schuell (NY- 
TRAN’”) and  Amersham Corp., respectively. The minigel and  trans- 
fer apparatus used for immunoblotting were both from Bio-Rad).  The 
c-aminocaproic  acid and  horseradish peroxidase were obtained  from 
Sigma. 
Development of Human Apo(a) Transgenic Mouse-Four human 
apo(a) expression constructs were made using either  the mouse me- 
tallothionein I (16), mouse albumin (17), cytomegalovirus (18) or 
mouse transferrin (TF  in plasmid name) enhancer/promoter 5’ se- 
quences  (19) linked to  a human  apo(a) cDNA (20). The apo(a) 
transgene  construct  (pTFlal7) was  derived from  the  apo(a) expres- 
sion vector pRK5ha17 (21). This expression vector contains the 
cytomegalovirus promoter/enhancer and an immunoglobulin G in- 
tron (22) fused to 25 nucleotides of the apo(a) 5’-untranslated se- 
quence,  the  apo(a)  secretion signal  sequence, 17  tandem copies of a 
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342-base pair sequence homologous to  the kringle 4 domain of plas- 
minogen followed  by a kringle 5 and protease-like domain. The 3'- 
untranslated region of apo(a) was fused to an SV40 early region 
polyadenylation signal. To make pTFlal7,  the cytomegalovirus pro- 
moter was  replaced with a 3-kilobase (kb) EcoRI-BamHI fragment of 
the mouse transferrin promoter (19). 
A 12.8-kb NotI-HpaI fragment from pTFlal7 was purified free of 
vector sequences and microinjected into fertilized C57  Bl/GxSJL F2 
hybrid mouse eggs (23). Mice that contained the transgene were 
identified by dot blot hybridization of  DNA extracted from tail tissue. 
One male mouse (275-4) expressed the transgene and was bred to 
C57  B1/6xSJL F1 females to establish a line. 
Enzyme-linked Immunoabsorbent (ELISA)  Assay of Plasma 
Apo(a)-The plasma levels of apo(a) in the mice were determined 
using a sandwich ELISA assay (11, 24). In this assay, the capture 
antibody is a rabbit anti-human  Lp(a) polyclonal antibody and  the 
detecting antibody is a mouse anti-human apo(a) monoclonal anti- 
body, IgG-IA2 conjugated to horseradish peroxidase (25). The assay 
was standardized using purified human Lp(a), and the values are 
reported as  Lp(a) total mass. Approximately one-third of Lp(a) mass 
is protein (apoB-100 and apo(a)) (3, 26), and  the molecular mass of 
the recombinant apo(a) approximates that of apoB-100 (-500,000 
kDa) (21). Therefore, the plasma concentration of the recombinant 
apo(a) was estimated to be one-sixth of the Lp(a) concentration 
determined by the ELISA assay. 
RNA  Blot Analysis of  Apo(a) Expression in Transgenic Mice-Total 
RNA was purified from various tissues (liver, kidney, jejunum, heart, 
brain,  testis, white fat) by guanidinium isothiocyanate-CsC1 centrif- 
ugation (27). An aliquot (10 pg) was size-fractionated on a 1.5% 
agarose-glyoxal gel, transferred to a nylon membrane, hybridized with 
a '"P-labeled 2.7-kb SmaI fragment from the pRK5ha17 expression 
construct  (21), and washed as previously described (28). After expo- 
sure to film, the membrane was stripped and re-hybridized with a 
'"P-labeled 3.1-kb EcoRI fragment from the mouse transferrin cDNA 
(kindly provided by Dr. G. Stanley McKnight, University of Wash- 
ington) and exposed to film. 
Immunoblot Analysis of Apo(a) Synthesis in Transgenic Mice- 
Mice  were anesthetized with an intraperitoneal injection of 90  mg/ 
kg sodium pentobarbital, and  the ascending aorta was cannulated and 
the right atrium slit. Mice  were perfused with 25  ml  of ice-cold 0.9% 
NaCl containing bovine serum albumin (2 mg/ml). The indicated 
tissues were  homogenized in four volumes of 150 mM NaCl, 1% (v/v) 
Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 1 mM 1,lO-phen- 
anthroline, 0.1 mM leupeptin, 1 pg/ml pepstatin, 0.5 pg/ml aprotinin, 
and 20  mM Tris-HCI, pH 7.4. The homogenate was centrifuged at 
800 X g for 2 h at 4 "C. The  supernatant was collected, and 80 pg  of 
total protein (in 10 gl) were  mixed with 5 p1 of buffer A (15% (w\v) 
SDS, 8 M urea, 5 mM dithiothreitol, 62.5 mM Tris-HC1, pH 8.0) and 
10 pl of loading buffer (10% (w/v) glycerol, 0.15% (w/v) bromphenol 
blue, 2.3% (w/v) SDS, 5% (v/v)  0-mercaptoethanol (@-ME), 62.5 mM 
Tris-HCl, pH 6.8). After boiling for 5 min, 15 pl of sample were 
loaded onto a 5% SDS-polyacrylamide gel and electrophoresis was 
performed for 1 h at 200 V at 4 "C. The proteins were transferred to 
nitrocellulose at 200 V for 1 h and immunoblotted as described (24) 
using IgG-1A2 conjugated to horseradish peroxidase (25). After wash- 
ing, the filter was  developed using the protocol and reagents of the 
ECL Western Blotting Detection System Kit'" (Amersham Corp.) 
and exposed to XAR-5 film (Kodak). 
Analysis ofApo(a) Distribution in Transgenic Mice  Plasma-A total 
of  100 pl of mouse and human plasma was adjusted to a density of 
1.215  g/ml with KBr, and ultracentrifugation was performed for 11 h 
a t  4 "C using a Beckman TLA-100 rotor at 436,000 X g. Aliquots (15 
pl) of total plasma, the top (d c 1.215 g/ml) and bottom (d > 1.215 
g/ml) fractions were added to 20 pl of buffer A and 50 pl of loading 
buffer. A 10-pl aliquot was boiled for 5 min and  then subjected to 
electrophoresis on a 5% SDS-polyacrylamide gel. Five pl of mouse 
plasma and one pl of human plasma (-0.5 pg  of Lp(a)) were adjusted 
to a volume of  20 pl in 0.9% NaCl. After the addition of 5 pl of sucrose 
dye (50% (w/v) sucrose, 0.625% (w/v) bromphenol blue, 0.2 M glycine, 
25 mM Tris,  pH  8.3), one-fifth of the  total volume  was loaded onto  a 
4% nondenaturing polyacrylamide gel. Electrophoresis was performed 
a t  4 "C for 2 h at 150 V. The gel was soaked for 12 h at 22 "C in 250 
ml of 10 mM dithiothreitol, 1.5 M Tris-HC1, pH 8.8. Immunoblotting 
was performed as described above. 
Infusion of Human and Mouse Lipoproteins into Apofa) Transgenic 
Mice-Human (h-)VLDL, h-LDL, and  h-HDL fractions were sepa- 
rated from plasma pooled  from  five normolipidemic subjects who had 
no detectable plasma Lp(a) by either the ELISA assay (11, 24) or 
immunoblotting (24). Mouse (m-)LDL (d = 1.019-1.063 g/ml) was 
isolated from 3 ml of plasma derived from five hepatoma-bearing 
mice that had markedly elevated LDL levels? The chemical compo- 
sition of mouse LDL was comparable to  that of human LDL (triglyc- 
eride to protein ratios: 0.46 uersus 0.40; total cholesterol to protein 
ratios: 1.5 versus 1.8) (29). The lipoproteins were dialyzed against 
0.15 M NaCl, and  then  the protein concentrations of LDL, HDL, and 
VLDL  were determined by the method of Lowry (30). The apoB-100 
content in purified VLDL  was estimated to be one-third of the total 
protein content  (31). 
Three transgenic mice  were anesthetized with sodium pentobarbi- 
tal (90 mg/kg). Each mouse received a 100-pl intravenous bolus of 
lipoproteins via the external jugular vein. The amount of lipoproteins 
injected was calculated so that  the molar ratio of plasma apo(a)  to 
injected apoB-100 or  HDL protein was 1 to 50.  Blood  was collected 
by retro-orbital  puncture at various time points  after the injection. 
For each set of experiments, 5 pl of each sample, prepared as described 
above, was loaded onto a 4% nondenaturing polyacrylamide gel under 
non-reducing conditions. After electrophoresis, the proteins were 
transferred to nitrocellulose and immunoblotted with IgG-1A2 as 
described. 
At each time point after the in uiuo infusion of h-VLDL, total 
lipoproteins were separated from 100 p1 of  mice plasma by ultracen- 
trifugation at d = 1.215 g/ml for 11 h at 436,000 X g  in  a Beckman 
TLA-100 rotor; 20-4 aliquots of the lipoprotein fractions were then 
mixed with 20 p1 of buffer A  and 50 p1 of loading buffer. The samples 
were boiled for 5 min, and 10 p1 were loaded onto a 12% SDS- 
polyacrylamide gel. An immunoblot was performed using a rabbit 
anti-human apoE immune serum as described (32). 
In Vitro Incubation of Human and Mouse Lipoproteins with Apofa) 
Transgenic Mice Plasma-Twenty pl of transgenic mouse plasma was 
incubated at 37 "C in a total volume of  40 p1 with the same purified 
lipoproteins that were used in the in uiuo experiments. The final 
molar ratio of apo(a)  to apoB-100 (and apo(a) to  total proteins  in the 
case of HDL) was 1 to 50. The incubations were performed for the 
same time intervals as  the in uivo experiments. A single aliquot of 
mouse plasma was incubated in 0.15 M NaCl for 6  h at 37 'C as a 
negative control. Immediately after the incubation, 15 pl of 0.15 M 
NaCl and 5 pl of sucrose dye  were added to a 5-pl aliquot from each 
time point and 10 pl were subjected to electrophoresis on a 4% 
nondenaturing polyacrylamide gel,  followed  by immunoblot analysis 
using IgG-1A2. 
Incubation of h-LDL with Plasma from Apofa) Transgenic mice in 
the Presence of edminocaproic Acid-Transgenic  mouse plasma (20 
pl) was incubated with h-LDL for 30 min in the absence or presence 
of 5, 20, 50, 100, 200, and 500 mM t-aminocaproic acid. After incu- 
bation, the samples were size-fractionated on 4% nondenaturing 
polyacrylamide gels and immunoblotting was performed as previously 
described. To determine if f-aminocaproic acid could disrupt the 
apo(a) . LDL complex formed in vitro or in uiuo, 20 pl of post-injection 
mouse plasma containing the  apo(a). LDL complex  was adjusted to a 
final concentration of  50,  200,  500 mM t-aminocaproic acid in 0.15 M 
NaCl and incubated for 15 min at 22 "C. Aliquots (10 pl)  were 
combined with 10 p1 of 0.15 M NaCl and 5 pl of sucrose dye.  Six  pl 
were loaded onto a 4% nondenaturing polyacrylamide gel and im- 
munoblotted with IgG-IA2. 
Stability of the Apo(a). LDL Complex in Presence of Denaturant 
and Chaotropic Agents-A 5-pl aliquot of the mouse plasma contain- 
ing the apo(a) . LDL complex obtained in vivo and in vitro was added 
to 50  pl of sample buffer containing 15% (w/v) SDS, 6 M urea, 0.2 M 
Tris-HC1, pH 6.8, in presence or absence of 30% (v/v) ethylene glycol. 
The samples were  boiled for 5 min, and 5 p1 were loaded onto  a 5% 
SDS-polyacrylamide gel and blotted with the IgG-IA2. Duplicate 
samples were prepared adding 5% (v/v) @ME prior to electrophoresis. 
RESULTS 
A total of 1762 eggs were microinjected with the apo(a) 
fusion genes and transferred into pseudopregnant females. 
Among 181 offspring, 61 contained the transgene as deter- 
mined by dot hybridization of DNA obtained from tail ho- 
mogenates. A sensitive ELISA immunoassay was used to 
measure plasma levels of Lp(a) in these mice (11, 24). The 
assay was standardized using purified human  Lp(a)  and the 
values are expressed as  Lp(a)  total mass. Of the 61 transgenic 
mice, only one of 21 pTFlal7 mice expressed the apo(a) 
transgene  and had a plasma Lp(a)  concentration of 9 mg/dl, 
R. E, Hammer, unpublished observations. 
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which corresponds to an apo(a) mass of -1.5 mg/dl. This 
founder mouse,  which contained the  apo(a) transgene  under 
the control of the  transferrin promoter (Fig. l), was mated, 
and a line was established. The heterozygous progeny of this 
founder  had plasma Lp(a) levels that ranged from 6 to  15 mg/ 
dl with a mean of  8.5 mg/dl. 
To determine the tissue  distribution of apo(a) expression, 
RNA blot analysis was performed using an apo(a)-specific 
probe (Fig. 2, panel A ) .  Apo(a) mRNA was detectable in  all 
tissues analyzed. When the same blot was stripped and hy- 
bridized with a mouse transferrin probe, expression of mouse 
transferrin was limited to  the liver, brain, testis (visible with 
longer exposure), and white fat. Previously, this 3.0-kb frag- 
ment of transferrin 5’-flanking DNA has been shown to 
faithfully direct expression of the human growth hormone 
gene (19) and the human low density lipoprotein receptor 
gene in transgenic mice (33). The loss of the normal hierarchy 
of transferrin expression in  this line of mice  may  be due to 
positional effects. 
apo(a) cDNA 
FIG. 1. Human  apo(a) expression construct. The expression 
vector (pTFlal7)  contains  the mouse transferrin  enhancer/promoter 
(black  box), an immunoglobulin intron (stippled  box), and  the  tran- 
scription  termination signal  from  SV40 (striped box). The recombi- 
nant apo(a) cDNA includes 25 nucleotides of the 5”untranslated 
region, signal sequence, five copies of the common kringle 4-like 
domain (the so-called “A” repeat), three copies of the “B” repeat 
(which differ from the “A” repeat by 3 base pairs), all the unique 
kringle 4-like domains (kringles 1 and 30-37), kringle 5, the  protease- 
like domain, and  part of the  3”untranslated region. 
A. 
Control Transgenic 1 
mTF 
B. 
500 KD - 
1 2 3 4 5 6 7 8  
The distribution of apo(a)  protein expression was  assessed 
by immunoblot analysis of solubilized tissue samples using an 
apo(a)-specific monoclonal antibody, IgG-1A2, and  the results 
are shown in  Fig. 2 (panel B ) .  Immunoreactive material was 
identified in all tissues examined (visible with longer  expo- 
sure).  A single immunoreactive band with an  apparent mass 
of -500 kDa was observed in the plasma of the transgenic 
mice (lane 3). In contrast,  there were two proteins visible in 
the tissue samples; the larger protein (-500 kDa) was of 
identical size to that seen in plasma, whereas the smaller 
protein (-300 kDa) was most prominent in  the liver and not 
present in the plasma. The same apo(a) cDNA has been 
expressed in a human kidney cell line (293 cells), and two 
proteins of the same size were identified (21). Pulse-chase 
experiments performed in the transfected 293 cells indicated 
that  the 300-kDa protein was a precursor of the mature, 500- 
kDa form (21), with the size difference presumably due to 
glycosylation. To determine the contribution of each tissue to 
apo(a) expression, densitometry was performed and  the rela- 
tive amount of tissue-specific expression was determined after 
correction for tissue weight. The liver was the major site of 
apo(a) synthesis and produced 15  times more apo(a) protein 
than  the brain and 40 times more than kidney. 
To determine  whether the apo(a)  in the mouse plasma was 
incorporated into a lipoprotein particle, total lipoproteins 
were isolated by ultracentrifugal flotation at  a density of  1.215 
g/ml. Aliquots of total plasma and  the  top (d  < 1.215 g/ml) 
and bottom (d > 1.215 g/ml) fractions were subjected to 
electrophoresis on  a 5% SDS-polyacrylamide gel under reduc- 
ing conditions, and immunoblotting was performed using the 
apo(a)-specific antibody (Fig.  3, top panel). In human plasma, 
all of the immunoreactive material was found in the top 
fraction (ie. associated with lipoproteins), whereas in the 
mouse plasma all the immunoreactive material was in the 
bottom fraction. These  results suggest that  the apo(a)  in the 
transgenic mice circulates free in plasma. 
To ensure that  the high salt buffers and/or  ultracentrifu- 
gation procedure used to isolate the lipoproteins had not 
disrupted the association of apo(a) with mouse lipoproteins, 
aliquots of total mouse plasma and  the  top  and bottom frac- 
tions were subjected to electrophoresis on  a 4% nondenaturing 
polyacrylamide gel  (Fig. 3, bottom panel). The  apo(a) immu- 
Human Mouse 
500kD - - oc4 
1 2 3 4 5 6 7 8 9  
FIG. 2. Tissue distribution of apo(a) mRNA and protein 
expression. Panel A, 10 pg of total RNA were extracted from  various 
tissues as described (27) and size-fractionated on a 1.5% agarose 
glyoxal gel. The RNA  was transferred to a  nylon membrane, hybrid- 
ized with an apo(a)-specific  probe, a 32P-labeled 2.7-kb SmaI fragment 
from  pRK5ha17 (> IOR cpm/pg) (21), then  stripped  and rehybridized 
with a ‘”P-labeled 3.1-kb EcoRI mouse transferrin cDNA probe. Panel 
R,  48 pg of total  protein from tissue homogenate  were  loaded onto a 
5% SDS-polyacrylamide gel under reducing conditions,  transferred 
to  a  nitrocellulose membrane  and blotted  with 20 pg/ml of a human 
apo(a)-specific monoclonal antibody, IgG-lA’, conjugated to horse- 
radish peroxidase (25).  The  membrane was exposed to  XAR-5 film 
for 3 min. 
LDL - m@ 
FIG. 3. Apo(a) distribution in transgenic mouse plasma. A 
total of 100 pl of plasma from humans  and from transgenic mice were 
subjected to ultracentrifugation at a density of  1.215 g/ml. Aliquots 
(2 pl) of total plasma, the  top fractions, and  the bottom fractions 
were electrophoresed on a 5% SDS-polyacrylamide gel (top  panel) or 
a 4% nondenaturing gel (bottompanel). After  electrophoretic transfer, 
the  proteins were immunoblotted using 20 pg/ml IgG-1A2 conjugated 
to horseradish  peroxidase as described under  “Experimental Proce- 
dures.” The  membrane was exposed to XAR-5 film for 1 min. 
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noreactive material in  human plasma migrated to a position 
that was identical to  the position of LDL. In mouse plasma, 
the  apo(a) migrated further  into  the gel, indicating that  it was 
not associated with LDL. The immunoreactive material in 
the bottom fraction  had an electrophoretic mobility identical 
to  that of the  apo(a) in mouse total plasma. Based on  these 
studies, it was concluded that  the bulk of the  apo(a) protein 
is not  tightly associated with lipoproteins in the plasma of 
transgenic mice. 
To determine  whether the  apo(a) synthesized by the mouse 
was capable of binding to LDL, human (h-)LDL was injected 
into  the external jugular vein of three transgenic mice and 
blood was collected by retro-orbital  puncture at  various times 
after  the injection. The plasma was loaded onto a 4% nonde- 
naturing polyacrylamide gel, and immunoblotting was per- 
formed with IgG-1A2 (Fig. 4A). Within 1 min after  the infu- 
sion of h-LDL, all of the apo(a)-reactive  material  shifted to a 
slower migrating form, reflecting the association of the free 
apo(a) with the infused lipoproteins. After 3 and 6 h, traces 
of free apo(a) were again detected (lanes 5 and 6). Previous 
metabolic studies have shown that h-LDL has a half-life of 
only  5  h  in mice (34). Therefore, at  the 3-6-h time  points, 
much of the injected h-LDL has presumably been metabo- 
lized. When h-HDL (Fig. 4C) was injected there was no rapid 
change  in the electrophoretic mobility of the apo(a)-immu- 
noreactive material. After 3-6 h, a small portion of apo(a) 
showed a shift upward in its mobility. The presence of this 
slower migrating band at  the  later time  points was reproduc- 
ible, but  the reason for its appearance is not known. When 
the same experiment was performed with h-VLDL, the  apo(a) 
associated with the lipoproteins, but in a delayed fashion 
when compared with LDL (Fig. 5A). 
The human lipoprotein fractions used in the in uiuo exper- 
iments were also incubated with transgenic mouse plasma in 
vitro at 37 "C and  then examined on  nondenaturing gels (Fig. 
4, panels B and D, and Fig. 5B). When mouse plasma was 
incubated with purified human  LDL or HDL, the results were 
similar to those  obtained in uiuo, i.e. apo(a) associated with 
h-LDL, but not h-HDL. However, when the experiment was 
Plasma IN VITRO IN VIVO rl h m  A. +hLDL B. +hLDL -hLDL - 
L a A 
c +hHDL D. +hHDL -hHDL 
h m  - -n 
B. +hVLDL -hVLDL 
m ~n 
FIG. 5. In  vivo injection  and in  vitro incubation of human 
VLDL in  transgenic mouse plasma. A total of 1.95  mg of human 
VLDL  (total  protein) was injected into  three  transgenic mice, and 
plasma  samples were obtained by retro-orbital  puncture at   the indi- 
cated times. The  samples from each  time  point were pooled, and 5-pl 
aliquots were size-fractionated  on a 4% nondenaturing gel and im- 
munoblottedwith  IgG-lAZ (panel A) .  A 100-pl aliquot from each time 
point was  subjected to  ultracentrifugation a t  a density of 1.215 g/ml, 
and 2 pl of the  top fraction were loaded onto a 12% SDS-polyacryl- 
amide gel. Immunoblotting was performed by incubating  the filter 
with a rabbit  anti-human  apo E antiserum (1:lOOO dilution)  and "'I- 
labeled goat  anti-rabbit  antibody (10' cpm/ml) (panel C). A total of 
45 pg of human  VLDL  (total  protein) was incubated in vitro with 20 
pl of mouse plasma a t  37 "C. The  samples were loaded onto a 4% 
nondenaturing minigel and  immunoblotted  with 20 pg/ml IgG-1A2 
(panel B ) .  All filters were exposed to XAR-5  film  for  2 min. 
performed with h-VLDL, less apo(a) associated with VLDL 
in uitro (Fig. 5B)  than had been observed in uiuo (Fig.  5A). 
In  the in uitro experiment (Fig. 5B), only 10% of the apo(a) 
was associated with lipoproteins after a 6-h incubation, in 
contrast  to  the in vivo experiment (Fig. 5A) in which 90% of 
the apo(a) was complexed with lipoproteins. In all four in 
uitro experiments using h-VLDL, there was a relative increase 
in association of apo(a) with lipoproteins with time, but  the 
proportion of apo(a)  that associated was never greater than 
10%. The association of apo(a) with lipoproteins at  the later 
time points may be due to in uitro chemical or enzymatic 
modification of the VLDL which exposes apo(a) binding sites 
on  the lipoprotein. The difference in the association of apo(a) 
with VLDL in vivo and in uitro suggests that apo(a) prefer- 
entially associates with a metabolic product of  VLDL, rather 
than with VLDL itself. 
VLDL secreted from the liver has multiple copies of apoli- 
poprotein E, as well as a single copy of apoB-100. As the 
particle undergoes lipolysis, the apoE proteins  are  transferred 
to other lipoproteins, and  the particle is converted to LDL. 
Therefore, the metabolism of the injected h-VLDL to h-LDL 
can be monitored by  following the disappearance of the hu- 
man apoE. At each time  point after  the infusion of VLDL, 
the lipoproteins were isolated by ultracentrifugation at a 
density of  1.215 g/ml and  an aliquot was denatured and size- 
fractionated  on  a  12% SDS-polyacrylamide gel.  An immuno- 
blot was performed using a polyclonal rabbit  anti-human apoE 
immune serum that does not cross-react with mouse apoE 
(Fig. 5C). The amount of human apoE in the mouse plasma 
declined at  the same time as  the amount of apo(a) associated 
with lipoproteins increased. This observation is consistent 
with the notion that large amounts of apo(a) bound to  the h- 
VLDL lipoprotein only when it had lost its apoE and had 
been converted to LDL. 
Approximately 70% of plasma cholesterol is transported as 
LDL in humans, but in mice the major cholesterol-carrying 
FIG. 4. In vivo injection and in vitro incubation of human 
LDL and HDL in  transgenic mouse plasma. The lipoproteins 
were separated by ultracentrifugation and dialyzed against 0.15 M 
NaCl.  A total of  0.65  mg of LDL or HDL  (total  protein) was injected 
into  three  transgenic mice and  plasma was  collected after 1 min, 30 
min, 1 h, 3 h, and 6 h (panels A and C). Fifteen pg of the same 
lipoproteins were incubated a t  37 "C with 20 p1 of mice plasma for 
the indicated times (panels B and D). The samples were electropho- 
resed on a 4% nondenaturing gel and  immunoblotted with the IgG- 
1A2 as described under "Experimental Procedures." The  filter was 
exposed to XAR-5 film for  2 min. lipoprotein is HDL (35). Mice have low levels  of plasma LDL 
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(35). To determine if the lack of association of the human 
apo(a) with mouse lipoproteins in  the  apo(a) transgenic mice 
was due to  the low concentration of circulating mouse LDL, 
excess amounts of purified mouse LDL were injected (Fig. 6). 
When mouse LDL was infused into  the transgenic animals, 
there was no association of apo(a) with  lipoproteins (Fig. 6A) .  
When mouse LDL was incubated in vitro with mouse plasma, 
only a small amount of apo(a) bound to mouse LDL (Fig. 
6B) .  We conclude that  the lack of association between human 
apo(a)  and mouse lipoproteins in  the transgenic mouse is due 
in  part  to  structural differences between human and murine 
LDL. 
Two different experiments were performed to evaluate if 
the stability of the  apo(a). LDL complex obtained in vivo and 
in vitro was comparable to  that of native  human  Lp(a). First, 
increasing concentrations of t-aminocaproic acid were added 
during the in vitro incubation of purified h-LDL and the 
apo(a)-containing mouse plasma. t-Aminocaproic acid is a 
lysine analogue that interferes with the binding of plasmino- 
gen and  apo(a)  to lysine residues (36). At a  concentration of 
100 mM, t-aminocaproic acid completely inhibited the asso- 
ciation of apo(a) with h-LDL (Fig. 7A) .  When t-aminocaproic 
acid was added in the identical concentrations to  apo(a) LDL 
complexes made in vivo, there was no disruption in the 
association of apo(a) with the lipoprotein (Fig. 7B) .  An iden- 
tical  result was obtained when the  apo(a). LDL complex was 
reconstituted in vitro (data not shown). 
Second, the stability of the reconstituted apo(a).  LDL com- 
plex was evaluated by boiling the sample for 5 min in  15% 
(w/v) SDS and 6 M urea  in the presence or absence of the 
chaotropic agent, ethylene glycol. The reaction was carried 
out in the presence of  500 mM t-aminocaproic acid to ensure 
that if any apo(a) dissociated from LDL, it could not re- 
associate with the lipoprotein prior to analysis by  gel electro- 
phoresis. The samples were loaded onto a 5% SDS-polyacryl- 
amide gel, and immunoblotted with IgG-IA2. The results of 
this analysis using human plasma, as well as LDL-apo(a) 
reconstituted in vivo or in vitro, are shown in Fig. 8. The 
apo(a) remained associated with LDL in  the  Lp(a) reconsti- 
tuted both in vivo and in vitro (panel A )  in  the absence (lunes 
3 and 4 )  or presence (lunes 7 and 8 )  of 30% (v/v)  ethylene 
glycol. As expected, in the presence of 5% (v/v) P-ME, the 
apo(a) dissociated from the apoB-100 of LDL (panel B) .  
DISCUSSION 
The major finding of this study is that expression of a 
human apo(a) transgene in mice results in synthesis and 
secretion of apo(a)  into plasma but failure of the  apo(a)  to 
plasma I IN VIVO IN VITRO I 
B. , + mLDL , -mADL 
FIG. 6. In vivo injection or in vitro incubation of mouse 
LDL with transgenic mouse  plasma. Mouse LDL, separated a t  
density 1.019-1.063 g/ml, was dialyzed against 0.15 M NaC1, and 0.65 
mg of total protein was infused into  three transgenic mice (panel A )  
or 15 pg was incubated in  vitro with 20 pl of transgenic mouse plasma 
at 37 “C (panel B ) .  The samples were electrophoresed on 4% nonde- 
naturing gels and immunoblotted using the IgG-1A2 (20 pg/ml) as 
described under  “Experimental Procedures.” 
A. 
[ 
B. 
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FIG. 7. Effect of c-aminocaproic acid on the association of 
apo(a) with h-LDL. A total of 15 pg of purified human LDL was 
incubated for 30 min a t  37 “C with 20 pl of transgenic mice plasma 
in  the presence of increasing  concentrations of c-aminocaproic acid. 
The samples were electrophoresed on  a 4% nondenaturing polyacryl- 
amide gel and immunoblotted  with the IgG-1A2 (panel A ) .  t-Amino- 
caproic acid was added in different  concentrations to plasma  contain- 
ing 2 pg of human  Lp(a), or to  Lp(a) reconstituted in vivo and in 
vitro as described under  “Experimental Procedures.” After 15 min at  
22 “C, 0.4  pg was size-fractionated  on  a 4% nondenaturing polyacryl- 
amide gel and immunoblotted using 20 pg/ml of IgG-1A2 (panel B ) .  
500 - 
200 - 200 - 
FIG. 8. Boiling of apo(a)*LDL complex formed in  vivo and 
in  vitro in presence of SDS, urea, and ethylene glycol. A total 
of 0.5 pg of human Lp(a) or apo(a).LDL complex reconstituted in 
vivo or in  vitro were boiled for 5 min in the presence of 15% SDS  and 
6 M urea  with (lanes 5-8) or without (lanes 1-4) 30% (v/v) ethylene 
glycol (panel A ) .  Identical  samples were treated with the same de- 
naturants plus 5% @-ME (panel B) .  In both experiments, 45 ng of 
protein were size-fractionated on 5% SDS-polyacrylamide gels and 
immunoblotted  with IgG-1A2 as described under  “Experimental Pro- 
cedures.’’ The filters were exposed to XAR-5 film for 2 min. 
properly associate with the mouse lipoproteins. Infusion of 
human LDL into the transgenic mice results in a rapid 
association of apo(a) with lipoproteins. This association is 
selective since the  apo(a) does not associate with h-HDL or 
m-LDL when these particles are infused into  the mice. There- 
fore, h-apo(a) fails to associate with the mouse lipoproteins 
in the transgenic mice because of structural differences be- 
tween mouse and human LDL, rather than  to  the low circu- 
lating levels of LDL in the mice. 
Is the association of apo(a) with human LDL particles 
observed in vivo identical to that of native Lp(a)? This 
question cannot be answered definitively since the chemical 
linkage between the  apo(a)  and h-LDL  in Lp(a)  has not been 
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fully characterized. When the  Lp(a) particle is subjected to 
reduction using either dithiothreitol or @-ME, the apo(a) 
dissociates from LDL, suggesting that apo(a) is joined to 
apoB-100 by a disulfide linkage. However, reduction of the 
Lp(a) particle also disrupts the secondary structure of apo(a) 
by breaking the numerous disulfide bonds in the cysteine-rich 
kringles. Therefore, despite the fact that  apo(a) dissociated 
from LDL  upon reduction, this dissociation is not proof of a 
disulfide linkage between apo(a)  and apoB. 
We have only limited information at present as to the 
molecular nature of the association of apo(a) with LDL. 
Preliminary  studies to characterize the human  LDL.  apo(a) 
complex formed in vivo and i n  vitro suggest that  Lp(a) has 
been successfully reconstituted. The fact that 1) e-aminoca- 
proic acid can prevent the association of apo(a) with LDL, 
but not induce its dissociation, and 2) the reconstituted  par- 
ticle can withstand boiling in 6 M urea suggests that  there is 
a covalent linkage formed between apo(a)  and apoB-100. 
The results of these experiments  are  consistent with there 
being a disulfide linkage between apo(a)  and apoB-100. The 
exact residues involved in the putative disulfide bond have 
not been pinpointed. Only kringle 36, the penultimate kringle 
4 repeat in the apo(a) gene, contains  a cysteine residue that 
is not involved in a  intra-kringle disulfide bond, so this is the 
presumed cysteine residue in apo(a)  that binds to apoB-100 
(20). The site of the cysteine residue in apoB-100 to which 
apo(a) binds has not been localized specifically. Unfortu- 
nately, the mouse apoB-100 gene has  not been  fully charac- 
terized, so the sequence differences responsible for this ob- 
served lack of association of apo(a) with mouse apoB-100 
cannot be pinpointed (37). 
In  contrast to  the rapid association of apo(a) with injected 
h-LDL, there was a delayed association of the  apo(a) with 
injected VLDL. This delay was inversely related to  the rate 
of disappearance of human  apoE from the plasma. This ob- 
servation suggests that  apo(a) preferentially associated with 
a metabolic product of VLDL (i.e. LDL)  rather than VLDL 
itself. In  support of this hypothesis was the observation that 
in vitro incubation of mouse plasma with purified human LDL 
resulted in a rapid association of apo(a) with LDL, whereas 
with VLDL there was only a  partial association of apo(a) with 
lipoproteins. The weaker association of apo(a) with VLDL 
may in part be attributed to  the size of the apo(a) isoform 
used in these experiments. Prior  studies have demonstrated 
that fat feeding in humans results in approximately 5% of 
apo(a) being associated with VLDL and chylomicrons (38). 
The larger apo(a) isoforms (i.e. >500,000 kDa) appear to 
preferentially associate with these triglyceride-rich particles. 
In  the current  study,  a relatively small apo(a) isoform 
(-500,000 kDa) was used, which may contribute to  the ob- 
served decreased association of apo(a) with VLDL i n  vivo and 
in vitro. 
Finally, in humans, does apo(a)  attach  to apoB-100 in the 
hepatocyte or in the plasma? It has been demonstrated that 
disulfide bonds between other apolipoproteins can form in 
plasma, e.g. between apoE3 and apoAII (39). Our results 
suggest that human apo(a) may  be secreted into plasma free 
of lipoproteins and associate with LDL in the circulation. A 
conclusive demonstration that  he  apo(a) joins LDL in 
plasma,  rather than in the hepatocyte, awaits the development 
of a transgenic mouse expressing both  h-apo(a)  and h-apo- 
BlOO genes. 
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